Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 9/20 | 0.46 |
| ▸ | HTR2B | P41595 | 6/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19233827 | 0.87 | HTR2C (0.49) | GID4HTR2CHTR2BHTR2ACFD | |
| SCHEMBL19234226 | 0.80 | GID4 (0.43) | GID4HTR2CHTR2BHTR2AKDM4E | |
| SCHEMBL19234227 | 0.80 | HTR2C (0.43) | GID4HTR2CHTR2BHTR2AKDM4E | |
| SCHEMBL19234370 | 0.79 | CFD (0.46) | GID4HTR2CHTR2BHTR2ACFD | |
| SCHEMBL19233917 | 0.77 | CFD (0.48) | GID4HTR2CHTR2BHTR2ACFD | |
| SCHEMBL19210755 | 0.77 | GID4 (0.55) | GID4HTR2CHTR2BHTR2ACFD | |
| SCHEMBL30052460 | 0.77 | GID4 (0.55) | GID4HTR2CHTR2BHTR2ACFD | |
| SCHEMBL19233964 | 0.77 | GID4 (0.55) | GID4HTR2CHTR2BHTR2ACFD | |
| SCHEMBL12479541 | 0.76 | CFD (0.47) | GID4HTR2CHTR2BHTR2ACFD | |
| SCHEMBL19234009 | 0.75 | CFD (0.48) | GID4HTR2CHTR2BHTR2ACFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |